Celldex Therapeutics, Inc. Financials

Market Capitalization $1.59 Billion as of Jan. 1, 2025

Valuations Metrics as of Jan. 25, 2025

Trailing PE	-8.23
Forward PE	-7.44
Price to Sales TTM	$159.74
Price to Book MRQ	$2.03
Enterprise to Revenue	84.27
Enterprise to EBITDA	-4.91

Financial Reports as of Sep. 30, 2024

Financials

Fiscal Year Ends	2023-12-31
Most Recent Quarter	2024-09-30
Profit Margin	0.00%
Operating Margin	-1633.53%
Return on Assets TTM	-19.73%
Return on Equity TTM	-29.84%

Income Statement

Revenue TTM	$9,976,000
Revenue per Share TTM	$0.16
Quarterly Revenue Growth	110.30%
Gross Profit TTM	$-137,060,992
EBITDA	$-171,060,992
Net Income to Common TTM	$-154,076,992
Diluted EPS TTM	$-2.58
Quarterly Earnings Growth YoY	110.35%

Balance Sheet

Total Cash MRQ	$755,998,976
Total Cash per Share MRQ	$11.40
Total Debt MRQ	$
Total Debt to Equity MRQ	0.39
Current Ratio MRQ	24.27
Book Value per Share MRQ	$11.85

Cash Flow

Operating Cash Flow TTM	$-157,835,008
Levered Free Cash Flow TTM	$-83,732,248

CLDX Stock Info as of Jan. 25, 2025

Stock Statistics

Shares Outstanding	66,344,200
Float Shares	66,161,126
Avg 10 Volume	1,021,950
Avg 30 Volume	None
Shares Short	8,086,627
Short Ratio	8.96
Short % of Shares	14.10%
% Held by Insiders	0.30%
% Held by Institutions	107.93%

Stock Price Summary

Beta	1.59
Fifty Two Week Low	$22.17
Fifty Two Week High	$53.18
Fifty Two Week Change	-51.46%
Day 50 MA	$25.65
Day 200 MA	$33.42

Dividends and Splits

Forward Annual Dividend Rate	$
Forward Annual Dividend Yield	%
Trailing Annual Dividend Rate	$0.00
Trailing Annual Dividend Yield	0.00%
Payout Ratio	0.00%
Dividend Date	2019-02-11
Ex Dividend Date
Last Split Factor
Last Split Date	2019-02-11